Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais, Paulo Cesar Ribeiro Barbosa & Lucas Oliveira Maia. (2022) Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey . Substance Use & Misuse 57:7, pages 1072-1081.
Read now
Read now
Andrew Kristoffer Dean. (2019) The enchanted snake and the forbidden fruit: the ayahuasca ‘fairy tale’ tourist. Journal of Marketing Management 35:9-10, pages 818-844.
Read now
Read now
Scott Kellogg. (2019) On Addiction, Complexity, and Freedom: Toward a Liberation-Focused Addiction Treatment. Journal of Psychoactive Drugs 51:1, pages 85-92.
Read now
Read now
Joselaine Ida Cruz & Solange Aparecida Nappo. (2018) Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence?. Journal of Psychoactive Drugs 50:3, pages 247-255.
Read now
Read now
Paulo
Cesar Ribeiro Barbosa, Irene
Maurício Cazorla, Joel
Sales Giglio & Rick Strassman. (2009) A Six-Month Prospective Evaluation of Personality Traits, Psychiatric Symptoms and Quality of Life in Ayahuasca-Naïve Subjects. Journal of Psychoactive Drugs 41:3, pages 205-212.
Read now
Read now
John D. Sellman, Michael P. Baker, Simon J. Adamson & Lloyd G. Geering. (2007) Future of God in recovery from drug addiction. Australian and New Zealand Journal of Psychiatry 41:10, pages 800-808.
Read now
Read now
JohnR. Baker. (2005) Psychedelic Sacraments. Journal of Psychoactive Drugs 37:2, pages 179-187.
Read now
Read now
Articles from other publishers (37)
Alberto Dubbini. (2023) Cultural Biases and Psychedelic Experiences: Western Scientific Perspectives about Amazonian Mestizo Therapeutic Traditions. OBM Integrative and Complementary Medicine 08:03, pages 1-23.
Crossref
Crossref
Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro & Lucas Oliveira Maia. (2023) The current state of ayahuasca research in animal models: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 125, pages 110738.
Crossref
Crossref
Bruno Gianfratti, Ricardo Tabach, Marna Eliana Sakalem, Talita Stessuk, Lucas Oliveira Maia & Elisaldo Araujo Carlini. (2022) Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity. Journal of Ethnopharmacology 285, pages 114865.
Crossref
Crossref
Miroslav Horák & Nahanga VerterMiroslav Horák & Nahanga Verter. 2022. Substance Use Disorders Treatment in Therapeutic Communities. Substance Use Disorders Treatment in Therapeutic Communities
51
78
.
Matthew W. Johnson. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology
213
227
.
David B. Yaden, Andrea P. Berghella, Paul S. Regier, Albert Garcia-Romeu, Matthew W. Johnson & Peter S. Hendricks. (2021) Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy 98, pages 103380.
Crossref
Crossref
David Dupuis. (2021) Psychedelics as Tools for Belief Transmission. Set, Setting, Suggestibility, and Persuasion in the Ritual Use of Hallucinogens. Frontiers in Psychology 12.
Crossref
Crossref
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer & Felix Betzler. (2021) Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 9:1, pages 48-58.
Crossref
Crossref
Miroslav Horák, Kristina Somerlikova, Rita Kocarova, Nahanga Verter, Hector Santiago Aldama Gonzalez & Mariah Cruz de Souza Tronco. (2021) Effective factors of addiction treatment communities in Peru, Nicaragua and Czechia. Therapeutic Communities: The International Journal of Therapeutic Communities 42:1, pages 43-58.
Crossref
Crossref
Miroslav Horák, Nahanga Verter & Kristina Somerlíková. (2021) Initiation Plants in Drug Addiction Treatment: The Purgahuasca Therapy. Anthropology of Consciousness 32:1, pages 33-54.
Crossref
Crossref
David M. O’Shaughnessy, Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai & Frances Quirk. (2021) Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. Therapeutic Advances in Psychopharmacology 11, pages 204512532098663.
Crossref
Crossref
A K Jaiswal, Kamna Sharma, S Lukose & M Gupta. (2020) Screening/Spot/Colour test of hallucinogens. IP International Journal of Forensic Medicine and Toxicological Sciences 5:3, pages 80-83.
Crossref
Crossref
Albert Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths & Matthew W. Johnson. (2020) Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry 10.
Crossref
Crossref
Miroslav Horák. 2020. LÉČBA DROGOVÉ ZÁVISLOSTI V TERAPEUTICKÝCH KOMUNITÁCH. LÉČBA DROGOVÉ ZÁVISLOSTI V TERAPEUTICKÝCH KOMUNITÁCH.
Edgar Antonio Estrella-Parra, Julio Cesar Almanza-Pérez & Francisco Javier Alarcón-Aguilar. (2019) Ayahuasca: Uses, Phytochemical and Biological Activities. Natural Products and Bioprospecting 9:4, pages 251-265.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira, Carolina Lança Pereira & Diana Dias da Silva. (2019) Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12:3, pages 184-194.
Crossref
Crossref
Roland R. Griffiths, Ethan S. Hurwitz, Alan K. Davis, Matthew W. Johnson & Robert Jesse. (2019) Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLOS ONE 14:4, pages e0214377.
Crossref
Crossref
Genís Ona & Sebastián Troncoso. (2019)
Long-lasting analgesic effect of the psychedelic drug
changa
: A case report
. Journal of Psychedelic Studies 3:1, pages 7-13.
Crossref
Crossref
Timothy I. Michaels, Jennifer Purdon, Alexis Collins & Monnica T. Williams. (2018) Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry 18:1.
Crossref
Crossref
Angélica Faleiros da Silva Maia, Leonardo da Silva Neto, Frederico Duarte Garcia, Rosemeire Brondi Alves & Ângelo de Fátima. 2018. Discovery and Development of Neuroprotective Agents from Natural Products. Discovery and Development of Neuroprotective Agents from Natural Products
415
434
.
Matthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson & Roland R Griffiths. (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology 31:7, pages 841-850.
Crossref
Crossref
Matthew W. Johnson & Roland R. Griffiths. (2017) Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14:3, pages 734-740.
Crossref
Crossref
Hector Vargas‐Perez, Taryn E. Grieder, Ryan Ting‐A‐Kee, Geith Maal‐Bared, Michal Chwalek & Derek van der Kooy. (2017) A single administration of the hallucinogen, 4‐acetoxy‐dimethyltryptamine, prevents the shift to a drug‐dependent state and the expression of withdrawal aversions in rodents. European Journal of Neuroscience 45:11, pages 1410-1417.
Crossref
Crossref
Ede Frecska, Petra Bokor & Michael Winkelman. (2016) The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. Frontiers in Pharmacology 7.
Crossref
Crossref
Marcelo S. Mercante. (2013) A ayahuasca e o tratamento da dependência. Mana 19:3, pages 529-558.
Crossref
Crossref
Stephen Ross. (2012) Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies. Psychiatric Clinics of North America 35:2, pages 357-374.
Crossref
Crossref
Doug Sellman. (2009) The 10 most important things known about addiction. Addiction 105:1, pages 6-13.
Crossref
Crossref
Nelson G.M. Gomes, Maria G. Campos, João M.C. Órfão & Carlos A.F. Ribeiro. (2009) Plants with neurobiological activity as potential targets for drug discovery. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:8, pages 1372-1389.
Crossref
Crossref
R. Paškulin. (2009) Iboga: entre mythe et réalitéIboga: between mythe and reality. Phytothérapie 7:1, pages 15-19.
Crossref
Crossref
MW Johnson, WA Richards & RR Griffiths. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22:6, pages 603-620.
Crossref
Crossref
X. Laqueille & S. Martins. (2008) L’Ayahuasca: clinique, neurobiologie et ambiguïté thérapeutique. Annales Médico-psychologiques, revue psychiatrique 166:1, pages 23-27.
Crossref
Crossref
Edward F. Pace-Schott & J. Allan Hobson. 2007. The Blackwell Companion to Consciousness. The Blackwell Companion to Consciousness
141
153
.
Roman Paškulin, Polona Jamnik, Marko Živin, Peter Raspor & Borut Štrukelj. (2006) Ibogaine affects brain energy metabolism. European Journal of Pharmacology 552:1-3, pages 11-14.
Crossref
Crossref
John H. Halpern & R. Andrew Sewell. (2005) Hallucinogenic botanicals of America: A growing need for focused drug education and research. Life Sciences 78:5, pages 519-526.
Crossref
Crossref
John H. Halpern, Andrea R. Sherwood, James I. Hudson, Deborah Yurgelun-Todd & Harrison G. PopeJrJr. (2005) Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans. Biological Psychiatry 58:8, pages 624-631.
Crossref
Crossref
John H Halpern. (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology & Therapeutics 102:2, pages 131-138.
Crossref
Crossref
Timothy I. Michaels, Jennifer Purdon, Alexis Collins & Monnica Williams. (2018) Inclusion of People of Color in Psychedelic-Assisted Psychotherapy: A Review of the Literature. SSRN Electronic Journal.
Crossref
Crossref